Corneal Endothelial Cell Loss After Endocapsular and Supracapsular Phacoemulsification: The PERCEPOLIS Randomized Clinical Trial

Abstract

whether the information presented is correct and relevant. 2 Furthermore, in our study, we used 2 other criteria, HONcode and JAMA, which further assess website rigorously, making our analysis thorough and robust.Currently, the modified DISCERN instrument that the authors present seems to be one developed by Azer. 3 Although we agree that this tool may be more specific, it was designed by Azer himself and has not been widely used as a standardized criterion. Therefore, until it has been adopted and used by others, it is a customized, nonstandardized variation of the original DISCERN instrument, which, on the other hand, has been used and cited many times in the literature. Ongoing research will likely lead to improved validated methods to analyze online data.

Letter Regarding: Corneal Endothelial Cell Loss After Endocapsular and Supracapsular Phacoemulsification: The PERCEPOLIS Randomized Clinical Trial

“…In the March 2023 issue of Cornea (Volume 42, Issue 3), Knutsson et al 1 posed 2 pertinent questions regarding our prospective randomized clinical trial (designated PERCEPOLIS). This trial, which involved 292 patients with normal to severe density cataracts and no other ocular complications, compared our subluxation phacoemulsification technique (Garde-à-vous) 2 with a standard endocapsular phacoemulsification technique (divide-and-conquer [DAC]) 3 for postoperative endothelial cell loss (ECL).…”